The Chk1 inhibitor SAR-020106 sensitizes human glioblastoma cells to irradiation, to temozolomide, and to decitabine treatment

BACKGROUND: Glioblastoma is the most common and aggressive brain tumour in adults with a median overall survival of only 14 months after standard therapy with radiation therapy (IR) and temozolomide (TMZ). In a novel multimodal treatment approach we combined the checkpoint kinase 1 (Chk1) inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Patties, Ina, Kallendrusch, Sonja, Böhme, Lisa, Kendzia, Eva, Oppermann, Henry, Gaunitz, Frank, Kortmann, Rolf-Dieter, Glasow, Annegret
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805470/
https://www.ncbi.nlm.nih.gov/pubmed/31639020
http://dx.doi.org/10.1186/s13046-019-1434-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805470/
https://www.ncbi.nlm.nih.gov/pubmed/31639020
http://dx.doi.org/10.1186/s13046-019-1434-2

Ejemplares similares